In a meta ‐ analysis by Wang et al. (2021) titled "Safety of Mesenchymal Stem Cell Transplantation: A Systematic Review and Meta-Analysis" (Journal of Translational Medicine, 11:124, doi:10.1186/1479-5876-11-124), 62 randomized clinical trials were reviewed, enrolling a total of 3,546 participants. The analysis clearly shows that actual malignancies related to MSC therapy are rarely reported. Consequently, in clinical practice - where MSCs are produced under strict quality control and used at early passages, as is the case with the MSCs used at LMI - the data indicate that MSC therapy does not increase the risk of cancer or tumor formation. Reference: Reference: In a meta ‐ analysis by Lalu et al. (2012) titled "Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials" (PLoS ONE 7(10): e47559, doi:10.1371/journal.pone.0047559), 36 clinical trials were reviewed, enrolling a total of 1,012 participants. In randomized controlled trials, the rate of cancer in MSC-treated patients was comparable to that in control groups - with no new cancers reported in otherwise healthy individuals. Consequently, in clinical practice - where MSCs are produced under strict quality control and used at early passages, as is the case with the MSCs used at LMI - the data indicate that MSC therapy does not increase the risk of cancer or tumor formation. Important Disclosure: In San Jose del Cabo (B.C.S), Mexico, where we conduct these treatments, our clinic operates under the regulatory oversight of COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), which is Mexico's equivalent of the U.S. Food and Drug Administration (FDA). COFEPRIS ensures the safety, efficacy, and quality of medical treatments and healthcare practices. Our clinic is licensed by COFEPRIS, guaranteeing that our treatments meet the highest standards of safety and efficacy. While our stem cell and other therapies are approved by COFEPRIS, they are not approved by the U.S. Food and Drug Administration (FDA). Patients considering these treatments should be aware of this distinction. As with any medical treatment, there are risks involved, and individual outcomes may vary. It is important to consult with your physician, thoroughly research the therapies, and carefully consider these risks before undergoing any stem cell or regenerative therapy. Disclaimer: The information provided on this site is for informational purposes only and should not be considered medical advice. This site is not intended for the promotion or solicitation of services to audiences where such promotion may conflict with local regulations, including the United States and Canada. If you have questions or concerns about your health, please consult a qualified healthcare professional. All therapies and treatments discussed are subject to applicable laws and regulations and may not be available in all regions. We encourage all patients to conduct their own research, consult with their healthcare providers, and make informed decisions based on the best available information.
Longevity Medical Institute (C) Copyright. All Rights Reserved.
08
Made with FlippingBook - Share PDF online